|
DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters in Dongguan. The partnership is centered on the local manufacturing, and commercialization of IVD products in Indonesia.
Mrs. Dyah, Chief Executive Officer of Fapon Indonesia Market, and Mr. Dicky, Head of the Business Development Division at Bio Farma, formally executed the agreement on behalf of their respective organizations. This collaboration represents a major advancement in localizing diagnostic technologies and upgrading Indonesia's healthcare industry.
Mrs. Dyah, CEO of Fapon Indonesia Market (right), and Mr. Dicky, Head of Business Development at Bio Farma (left), during the signing ceremony.
"We are excited to strengthen our partnership with PT Fapon to localize the production of high-end IVD products in Indonesia," said Mr. Shadiq Akasya, President Director of Bio Farma. "This collaboration will bolster our national capabilities in medical device manufacturing, thereby enabling broader disease detection coverage across Indonesia."
Mr. Ben He, President of Fapon Biotech, stated, "PT Fapon is deeply committed to fostering the growth of Indonesia's healthcare industry through meaningful technology partnerships. We are confident that this technology transfer and localization project will provide Indonesia with cutting-edge diagnostic solutions, and help build a more resilient and sustainable healthcare future."
PT Fapon is Fapon Group's first overseas manufacturing base, dedicated to supplying the Indonesian and regional markets with diagnostic products and solutions that meet international standards. Bio Farma, with a legacy spanning over 130 years, is a leading national life science enterprise in Indonesia, boasting extensive expertise in the research, development, production, and distribution of vaccines, biologics, and pharmaceutical products.
This partnership marks a significant milestone in PT Fapon's strategy to deepen its local roots and empower the autonomous development of Indonesia's medical industry. Looking ahead, both parties plan to explore further collaborative opportunities in medical innovation and technology transferring, jointly driving progress in healthcare across Indonesia and Southeast Asia.
About PT Fapon Bioindustries Indonesia
PT Fapon Bioindustries Indonesia, located in West Java, is Fapon's first international manufacturing base. The facility is built and operated in strict compliance with ISO 14644 standards and is dedicated to delivering high-quality in-vitro diagnostic (IVD) products and solutions to the Indonesian market. Leveraging the Fapon Group's global R&D, manufacturing, and service network, PT Fapon actively introduces advanced diagnostic technologies to support the growth of Indonesia's local healthcare industry, improve diagnostic accessibility, and contribute to enhancing public health in the country.
About PT Bio Farma (Persero)
PT Bio Farma (Persero) is a world-class, globally competitive life science company that has a role to provide and develop international standard life science products to improve the quality of life. Supported by competence, experience and learning process for more than 130 years, Bio Farma is present as part of the struggle to save and improve the quality of human life. Given the important role in building the nation's health, Bio Farma's existence is maintained from time to time.
DONGGUAN, China, Dec. 8, 2025 /PRNewswire/ -- PT Fapon Bioindustries Indonesia (referred to as "PT Fapon") and the Indonesian state-owned pharmaceutical holding company PT Bio Farma (Persero) (referred to as "Bio Farma") officially signed a cooperation agreement at Fapon's headquarters in Dongguan. The partnership is centered on the local manufacturing, and commercialization of IVD products in Indonesia.
Mrs. Dyah, Chief Executive Officer of Fapon Indonesia Market, and Mr. Dicky, Head of the Business Development Division at Bio Farma, formally executed the agreement on behalf of their respective organizations. This collaboration represents a major advancement in localizing diagnostic technologies and upgrading Indonesia's healthcare industry.
Mrs. Dyah, CEO of Fapon Indonesia Market (right), and Mr. Dicky, Head of Business Development at Bio Farma (left), during the signing ceremony.
"We are excited to strengthen our partnership with PT Fapon to localize the production of high-end IVD products in Indonesia," said Mr. Shadiq Akasya, President Director of Bio Farma. "This collaboration will bolster our national capabilities in medical device manufacturing, thereby enabling broader disease detection coverage across Indonesia."
Mr. Ben He, President of Fapon Biotech, stated, "PT Fapon is deeply committed to fostering the growth of Indonesia's healthcare industry through meaningful technology partnerships. We are confident that this technology transfer and localization project will provide Indonesia with cutting-edge diagnostic solutions, and help build a more resilient and sustainable healthcare future."
PT Fapon is Fapon Group's first overseas manufacturing base, dedicated to supplying the Indonesian and regional markets with diagnostic products and solutions that meet international standards. Bio Farma, with a legacy spanning over 130 years, is a leading national life science enterprise in Indonesia, boasting extensive expertise in the research, development, production, and distribution of vaccines, biologics, and pharmaceutical products.
This partnership marks a significant milestone in PT Fapon's strategy to deepen its local roots and empower the autonomous development of Indonesia's medical industry. Looking ahead, both parties plan to explore further collaborative opportunities in medical innovation and technology transferring, jointly driving progress in healthcare across Indonesia and Southeast Asia.
About PT Fapon Bioindustries Indonesia
PT Fapon Bioindustries Indonesia, located in West Java, is Fapon's first international manufacturing base. The facility is built and operated in strict compliance with ISO 14644 standards and is dedicated to delivering high-quality in-vitro diagnostic (IVD) products and solutions to the Indonesian market. Leveraging the Fapon Group's global R&D, manufacturing, and service network, PT Fapon actively introduces advanced diagnostic technologies to support the growth of Indonesia's local healthcare industry, improve diagnostic accessibility, and contribute to enhancing public health in the country.
About PT Bio Farma (Persero)
PT Bio Farma (Persero) is a world-class, globally competitive life science company that has a role to provide and develop international standard life science products to improve the quality of life. Supported by competence, experience and learning process for more than 130 years, Bio Farma is present as part of the struggle to save and improve the quality of human life. Given the important role in building the nation's health, Bio Farma's existence is maintained from time to time.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
PT Fapon and PT Bio Farma Forge Strategic Partnership to Advance IVD Localization and Innovation in Indonesia
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- In 2025, Mantle entered a new phase of its evolution. What began as a high-performance Layer-2 rapidly transformed into a full-stack on-chain financial ecosystem, uniting infrastructure, liquidity, institutions, builders, creators, and global communities.
The release of Mantle "2025 RWApped" captures this shift — a year defined by accelerating institutional momentum, rapid RWA expansion, and Mantle's growing role as the distribution layer connecting traditional finance with on-chain liquidity.
Ecosystem MoMNTum at Scale
In 2025, Mantle reached multiple ecosystem all-time highs, signaling its progression into a more mature, institution-ready network:
- Top-30 ranking on CoinMarketCap & CoinGecko at ATH
- Treasury peaked above $7.9B
- TVL surpassed $2.2B
- Stablecoin supply exceeded $750M
- Global community topped 1M members
- 200+ ecosystem partners and dApps across DeFi, RWAs, infrastructure, and consumer applications
These milestones marked Mantle's emergence as a credible on-chain venue for real-world finance.
Infrastructure Built for the RWA Era
Two major upgrades in 2025 established Mantle as a high-throughput, institutional-grade settlement layer:
- EigenLayer Integration: As the first and largest L2 to partner with EigenLayer, Mantle unlocked modular security, shared validation, enhanced censorship resistance, and enterprise-grade scalability.
- OP-Succinct via Succinct Labs: Mantle became the first OP Stack L2 to launch as a ZK Validity Rollup, and the largest ZK rollup by TVL, enabling faster settlement, safer execution, and frictionless capital flow between real-world and digital markets.
Together, these upgrades positioned Mantle as an execution and settlement layer for compliant, high-volume RWA activity.
Deep CeFi Integration with Bybit
A core driver of Mantle's 2025 expansion was its deep, native integration across the Bybit ecosystem, embedding $MNT across spot markets, institutional trading desks, and VIP liquidity programs. This transformed $MNT into a true CeFi-native asset, driving large-scale participation from both retail and institutional traders and forming a powerful distribution bridge between centralized exchange liquidity and on-chain finance.
Global Liquidity Across CeFi and DeFi
As adoption scaled, Mantle's liquidity footprint expanded worldwide across platforms including Coinbase, Hyperliquid, Moomoo, Backpack, and Coinhako, ensuring seamless access for retail users, professional traders, and institutions deploying capital into Mantle-native applications.
Builders, Creators & Global Community
Ecosystem growth in 2025 was powered by people. Mantle hosted its largest global hackathon to date with 800+ builders, and launched the industry's first RWA Scholars Program, selecting 6 scholars from 5 countries from over 2,000 global creator submissions.
Mantle also activated its community worldwide through:
- 67 global AMAs
- 25 international events
- 12 developer meetups
- 19 online activations
From ETHDenver and TOKEN2049 to Korea Blockchain Week and CCCC Lisbon, Mantle's presence became truly global.
Key Strategic Milestones
- 5 Aug 2025 — The Bybit Era Begins: Mantle became the heart of Bybit's on-chain ecosystem; Helen Liu and Emily Bao joined as Key Advisors.
- 1 Oct 2025 — The RWA Pivot: Mantle went all-in on RWAs with major integrations including Anchorage, Backed/xStocks, Aave, DMZ Finance, Ethena, Agora, and Securitize.
- Oct 2025 — Builders Activated: Launch of Mantle's First Global Hackathon.
- Nov 2025 — Education Meets RWAs: Debut of the RWA Scholars Program at CCCC Lisbon.
By year-end, Mantle had transitioned from RWA strategy to full ecosystem execution, firmly positioning itself as a distribution layer connecting traditional finance with on-chain liquidity.
Looking Ahead to 2026
With infrastructure hardened, liquidity globalized, and institutional momentum accelerating, Mantle enters 2026 focused on:
- Scaling real-world assets on-chain
- Deepening institutional finance integration
- Expanding global distribution and developer adoption
The MoMNTum continues.
About Mantle
Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with onchain liquidity and access real-world assets, powering how real-world finance flows.
With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network's partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, OP-Succinct and EigenLayer.
For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel
For media enquiries, please contact: contact@mantle.xyz
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Mantle "2025 RWApped": A Year of Unstoppable MoMNTum and Global RWA Expansion
